Trial Profile
A retrospective study to compare the efficacy and safety of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2016 New trial record